Compounds > dilactitol tyramine

Page last updated: 2024-12-07

dilactitol tyramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dilactitol tyramine: labeled with (125)I for VLDL lipoprotein catabolism identification [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	126958
MeSH ID	M0140930

Synonyms (7)

Synonym
dilactitol tyramine
98503-07-2
125i-dlt
dilactitol-tyramine
tyramine dilactitol
d-glucitol, 1,1'-((2-(4-hydroxy-3-(iodo-125i)phenyl)ethyl)imino)bis(4-o-beta-d-galactopyranosyl-
(2r,3r,4r,5s)-6-[2-(4-hydroxy-3-iodophenyl)ethyl-[(2s,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexyl]amino]-3-[(3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,4,5-tetrol

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (22.22)	18.7374
1990's	12 (66.67)	18.2507
2000's	2 (11.11)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.64 (24.57)
Research Supply Index	2.94 (2.92)
Research Growth Index	4.59 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.64)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	18 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	1.97	1	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
tyramine [no description available]	9.23	18	0	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
corticosterone [no description available]	1.97	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
1,2-dipalmitoylphosphatidylcholine 1,2-Dipalmitoylphosphatidylcholine: Synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of PULMONARY SURFACTANTS.	2	1	0
rhenium Rhenium: A metal, atomic number 75, atomic weight 186.207, symbol Re.	1.98	1	0	manganese group element atom
acetylgalactosamine Acetylgalactosamine: The N-acetyl derivative of galactosamine.	1.98	1	0	N-acetyl-D-hexosamine; N-acetylgalactosamine	Escherichia coli metabolite; human metabolite; mouse metabolite
4-aminopyrazolo(3,4-d)pyrimidine 4-aminopyrazolo(3,4-d)pyrimidine: adenine analog which suppresses growth of E coli & Bacillus cereus; inhibits cell growth & purine biosynthesis in rat hepatoma	1.97	1	0
phenylalanyl-prolyl-arginine-chloromethyl ketone phenylalanyl-prolyl-arginine-chloromethyl ketone: do not confuse with Pro-Phe-Arg-CH2-Cl or with Phe-Phe-Arg-CH2-Cl, both sometimes also referred to as PPACK	2.38	2	0
cholesteryl linoleyl ether cholesteryl linoleyl ether: analog of cholesterol linoleate	2.38	2	0
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	2	1	0	1,2-diacyl-sn-glycero-3-phosphocholine
bucladesine Bucladesine: A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed). bucladesine : A 3',5'-cyclic purine nucleotide that is the 2'-butanoate ester and 6-N-butanoyl derivative of 3',5'-cyclic AMP.	1.97	1	0	3',5'-cyclic purine nucleotide
hirudin Hirudin: A 65-residue polypeptide from LEECHES.	1.98	1	0
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	1.98	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Adenocarcinoma, Basal Cell [description not available]	0	1.98	1	0
Cancer of Lung [description not available]	0	2.39	2	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	1.98	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	2.39	2	0
Cancer of Kidney [description not available]	0	1.98	1	0
Cancer of Ovary [description not available]	0	1.98	1	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	0	1.98	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	1.98	1	0
Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.	0	1.98	1	0
Carcinoma, Non-Small Cell Lung [description not available]	0	1.99	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	0	1.99	1	0
Blood Clot [description not available]	0	2.38	2	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	0	2.38	2	0
Experimental Neoplasms [description not available]	0	1.97	1	0
Osteogenic Sarcoma [description not available]	0	1.97	1	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	0	1.97	1	0
Elevated Cholesterol [description not available]	0	1.96	1	0
Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.	0	1.96	1	0